Экспрессия лиганда рецептора программируемой клеточной гибели 1 (PD-L1) при раке желудка: обзор литературы

Рак желудка в настоящее время является одним из самых распространенных онкологических заболеваний, что обусловливает значимость и актуальность исследований в этой области. ингибиторы иммунологических контрольных точек ранее продемонстрировали свою эффективность и безопасность при различных солидных опухолях, однако, что касается рака желудка, на сегодняшний день представлены неоднозначные результаты. клетки опухоли экспрессируют лиганд запрограммированной  смерти 1 (PD-L1), который связывается с рецептором запрограммированной смерти 1 (PD-1). иммунная защита играет ключевую роль в инициации и прогрессировании заболевания. понимание регуляторного механизма PD-L1 при раке желудка может привести к существенному прогрессу в иммунотерапии, а также способствовать адекватному отбору пациентов для лечения ингибиторами иммунологических контрольных точек. в обзоре мы провели углубленное исследование экспрессии PD-L1 и регуляторных иммуносупрессивных механизмов при раке желудка, методов оценки PD-L1-статуса, а также изучили результаты текущих клинических испытаний, в которых были рассмотрены ингибиторы иммунологических контрольных точек в комбинации с химиотерапией и без нее при данной онкологической патологии.

1. Bray F., Ferlay J., Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. Cancer J Clin 2018;68(6): 394–424. DOI: 10.3322/caac.21492

2. Состояние онкологической помощи населению России в 2018 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2019. 236 с.

3. Злокачественные новообразования в России в 2018 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М. : МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2019. 250 с.

4. Ishida Y., Agata Y., Shibahara K., Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992;11(11):3887–95. DOI: 10.1002/j.1460-2075.1992.tb05481.x

5. Agata Y., Kawasaki A., Nishimura H. et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 1996;8(5):765–72. DOI: 10.1093/intimm/8.5.765

6. Nishimura H., Nose M., Hiai H. et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999;11(2): 141–51. DOI: 10.1016/S1074-7613(00)80089-8

7. Freeman B.G.J., Long A.J., Iwai Y. et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000;192(7):1028–34. DOI: 10.1084/jem.192.7.1027

8. Iwai Y., Ishida M., Tanaka Y. T. Okazaki et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 2002;99(19):12293–7. DOI: 10.1073/pnas.192461099

9. Taube J.M., Anders R.A., Young G.D. et al. Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012;4(127):127ra37. DOI: 10.1126/scitranslmed.3003689

10. Tivol E.A., Borriello F., Schweitzer A.N. et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995;3(5):541–7. DOI: 10.1016/1074-7613(95)90125-6

11. Weber J., Thompson J.A., Hamid O. et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009;5(17):5591–8. DOI: 10.1158/1078-0432.CCR-09-1024

12. Wolchok J.D., Neyns B., Linette G. et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010;11(2):155–64. DOI: 10.1016/S1470-2045(09)70334-1

13. O’Day S.J., Maio M., Chiarion-Sileni V. et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol 2010;21(8):1712–7. DOI: 10.1093/annonc/mdq013

14. Hodi F.S., O’Day S.J., McDermott D.F. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363(8):711–23. DOI: 10.1056/NEJMoa1003466

15. Topalian S.L., Hodi F.S., Brahmer J.R. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366(26):2443–54. DOI: 10.1056/NEJMoa1200690

16. Fuchs C.S., Doi T., Jang R.W. et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol 2018;4(5):e180013. DOI: 10.1001/jamaoncol.2018.0013

17. Ott P.A., Bang Y.-J., Piha-Paul S.P. et al. T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028. J Clin Oncol 2019;37(4):318–27. DOI: 10.1200/JCO.2018.78.2276

18. Böger C., Behrens H.M., Mathiak M. et al. PD-L1 is an independent prognostic predictor in gastric cancer of Western patients. Oncotarget 2016;7(17):24269–83. DOI: 10.18632/oncotarget.8169

19. Frank G.A., Kuznetsova O.A., Zavalishina L.E. et al. PD-L1 status in breast cancer. Arkh Patol 2019;81(2):3–9. DOI: 10.17116/patol2019810213

20. Garon E.B., Rizvi N.A., Hui R. et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372(21):2018–28. DOI: 10.1056/NEJMoa1501824

21. Dolled-Filhart M., Locke D., Murphy T. et al. Development of a prototype immunohistochemistry assay to measure programmed death ligand-1 expression in tumor tissue. Arch Pathol Lab Med 2016;140(11):1259–66. DOI: 10.5858/arpa.2015-0544-OA

22. Dolled-Filhart M., Roach C., Toland G. et al. Development of a companion diagnostic for pembrolizumab in non-small cell lung cancer using immunohistochemistry for programmed death ligand-1. Arch Pathol Lab Med 2016;140(11):1243–9. DOI: 10.5858/arpa.2015-0542-OA

23. Muro K., Chung H.C., Shankaran V. et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol 2016;17(6):717–26. DOI: 10.1016/S1470-2045(16)00175-3

24. Kulangara K., Zhang N., Corigliano E. et al. Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer. Arch Pathol Lab Med 2019;143(3):330–7. DOI: 10.5858/arpa.2018-0043-OA

25. Fuchs C.S., Doi T., Jang R.W. et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol 2018;4(5):1–8. DOI: 10.1001/jamaoncol.2018.0013

26. Bang Y.J., Kang Y.-K., Catenacci D.V. et al. Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study. Gastric Cancer 2019;22(4):828–37. DOI: 10.1007/s10120-018-00909-5

27. Shitara K., Özgüroğlu M., Bang Y.-J. et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastrooesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet 2018;392( 10142): 123–33. DOI: 10.1016/S0140-6736(18)31257-1

28. Tabernero K.S.J., Van Cutsem E., Bang Y. et al. Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: the phase 3 KEYNOTE-062 study. Ann Oncol 2019;30(Suppl. 4):iv152. DOI: 10.1093/annonc/mdz183

29. O’Malley D.P., Yang Y., Boisot S. et al. Immunohistochemical detection of PD-L1 among diverse human neoplasms in a reference laboratory: observations based upon 62,896 cases. Mod Pathol 2019;32(7):929–42. DOI: 10.1038/s41379-019-0210-3

30. Yamashita K., Iwatsuki M., Harada K. et al. Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohisto-chemical staining in patients with advanced gastric cancer. Gastric Cancer 2020;23(1):95–104. DOI: 10.1007/s10120-019-00999-9

31. Kang Y.K., Boku N., Satoh T. et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;390(10111):2461–71. DOI: 10.1016/S0140-6736(17)31827-5

32. Janjigian Y.Y., Bendell J., Calvo E. et al. CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer. J Clin Oncol 2018;36(28):2836–44. DOI: 10.1200/JCO.2017.76.6212

33. Ma J., Li J., Qian M. et al. PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28-8 and E1L3N). Diagn Pathol 2018;13(1):1–10. DOI: 10.1186/s13000-018-0766-0

34. Park Y., Koh J., Na H.Y. et al. PD-L1 testing in gastric cancer by the combined positive score of the 22C3 PharmDx and SP263 assay with clinically relevant cut-offs. 2020 Cancer Res Treat 2020;52(3):661–70. DOI: 10.4143/crt.2019.718

35. Zhang M., Dong Y., Liu H. et al. The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patients. Sci Rep 2016;6:37933. DOI: 10.1038/srep37933

36. Chang H., Jung W.Y., Kang Y. et al. Programmed death-ligand 1 expression in gastric adenocarcinoma is a poor prognostic factor in a high CD8+ tumor infiltrating lymphocytes group. Oncotarget 2016;7(49):80426–34. DOI: 10.18632/oncotarget.12603

37. Harada K., Dong X., Estrella J.S. et al. Tumor-associated macrophage infiltration is highly associated with PD-L1 expression in gastric adenocarcinoma. Gastric Cancer 2018;21(1):31–40. DOI: 10.1007/s10120-017-0760-3

38. Li Y., Wang J., Ke X.Y. Research update on PD-1/PD-L1 pathway in hematological diseases. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2011;19(6):1523–7. (In Chinese).